Hyperglycemia induced by acute central fluoxetine administration: Role of the central CRH system and 5-HT3 receptors

Neuropeptides

Volumn 38, Issue 2-3, 2004, Pages 98-105

  Carvalho, F ^a   Barros, D ^a   Silva, J ^a   Rezende, E ^a   Soares, M ^b   Fregoneze, J ^b   De Castro E Silva, E ^b  

^a UNIVERSIDADE DO ESTADO DA BAHIA   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Helical CRH; 5 HT3 receptors; CRH; Fluoxetine; Hyperglycemia; Insulin; LY 278,584; Ondansetron; Serotonin

Indexed keywords

1 METHYL 3 INDAZOLECARBOXYLIC ACID N TROPANYLAMIDE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; FLUOXETINE; GLUCOSE; INSULIN; ONDANSETRON; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN THIRD VENTRICLE; CANNULATION; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CORTICOTROPIN-RELEASING HORMONE; FLUOXETINE; HYPERGLYCEMIA; INJECTIONS, INTRAVENTRICULAR; MALE; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN UPTAKE INHIBITORS;

ANIMALIA;

EID: 3042546555     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2004.04.004     Document Type: Article

References (52)

1. Abi-Dargham A., Laruelle M., Wong D.T., Robertson D.W., Weinberg D.R., Kleinman J.E. Pharmacological and regional characterization of [3H]LY278584 binding sites in human brain. J. Neurochem. 60:1993;730-737
2. Amsterdam J.D., Hornig-Rohan M., Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J. Clin. Psychiatry. 55(9):1994;394-400
3. Bagdy G., Calogero A.E., Szemeredi K., Gomez M.T., Murphy D.L., Chrousos G.P., Gold P.W. β-Endorphin responses to different serotonin agonists: involvement of corticotropin-releasing hormone, vasopressin and direct pituitary action. Brain Res. 537:1990;227-232
4. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 38:1999;1083-1152
5. Barseghian G., Lev-Ran A., Hwang D., Josefsberg Z., Tomkinson C. Fenfluramine inhibits insulin secretion and potentiates glucagon release by the perfused rat pancreas. Eur. J. Pharmacol. 96:1983;53-59
6. 2 receptor agonist DOI. Eur. J. Pharmacol. 213:1992;41-46
7. Bovetto S., Rouillard C., Richard D. Role of CRH in the effects of 5-HT-receptor agonists on food intake and metabolic rate. Am. J. Physiol. 271:1996;R1231-R12388
8. Brown M.R., Fisher L.A., Webb V., Vale W.W., Rivier J.E. Corticotropin-releasing factor: a physiologic regulator of adrenal epinephrine secretion. Brain Res. 328(2):1985;355-357
9. Brown M.R., Fisher L.A., Spiess J., Rivier C., Rivier J., Vale W. Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism. Endocrinology. 111(3):1982;928-931
10. 3 receptor stimulation by m-CPBG increases blood glucose in rats. Horm. Metab. Res. 34:2002;55-61
11. Cetin Y. Biogenic amines in the guinea pig endocrine pancreas. Life Sci. 50:1992;1343-1350
12. Chaouloff F. Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res. Rev. 18:1993;1-32
13. 1A and alpha-2 adrenergic receptors mediate the hyperglycemic and hypoinsulinemic effects of 8-hydroxy-2-(di-n-propylamino)tetralin in conscious rat. J. Pharmacol. Exp. Ther. 243:1987;1159-1166
14. 2 receptors are involved in the adrenal catecholamine-releasing and hyperglycemic effects of the 5-hydroxytryptamine indirect agonist D-fenfluramine in the conscious rat. J. Pharmacol. Exp. Ther. 260:1992;1008-1016
15. Chaouloff F., Laude D., Baudrie V. Ganglionic transmission is a prerequisite for the adrenaline-releasing and hyperglycemic effects of 8-OH-DPAT. Eur. J. Pharmacol. 185:1990;11-18
16. Deeg M.A., Lipkin E.W. Hypoglycemia associated with the use of fluoxetine. West. J. Med. 164(3):1996;262
17. Ding W.G., Fujimura M., Tooyama I., Kimura H. Phylogenetic study of serotonin-immunoreactive structures in the pancreas of various vertebrates. Cell Tissue Res. 263:1991;237-243
18. Durcan M.J., Wozniak K.M., Linnoila M. Modulation of the hypothermia and hyperglycaemic effects of 8-OH-DPAT by α2-adrenoceptor antagonists. Br. J. Pharmacol. 102:1991;222-226
19. Eckart K., Radulovic J., Radulovic M., Jahn O., Blank T., Stiedl O., Spiess J. Actions of CRF and its analogs. Curr. Med. Chem. 6(11):1999;1035-1053
20. Feldman J.M., Lebovitz H.E. Specificity of serotonin inhibition of insulin release from golden hamster pancreas. Diabetes. 19:1970;475-479
21. Feldman S., Newman M.E., Gur E., Weidenfeld J. Role of serotonin in the amygdala in hypothalamo-pituitary-adrenocortical responses. Neuroreport. 9:1998;2007-2009
22. Fletcher S., Barnes N.M. Desperately seeking subunits: are native 5-HT3 receptors really homomeric complexes? Trends Pharmacol. Sci. 19:1998;212-215
23. 4 receptor antagonists. Med. Res. Rev. 17:1997;163-214
24. Gunion M.W., Rosenthal M.J., Taché Y., Miller S., Butler B., Zib B. Intrahypothalamic microinfusion of corticotropin-releasing factor elevates blood glucose and free fatty acids in rats. J. Auton. Nerv. Syst. 24:1988;87-95
25. Hanley N.R., Van de Kar L.D. Serotonin and the neuroendocrine regulation of the hypothalamic-pituitary-adrenal axis in the health and disease. Vitam. Horm. 66:2003;189-255
26. 3 receptor. Biophys. J. 84:2003;1720-1733
27. Harms P.G., Ojeda S.R. A rapid and simple procedure for chronic cannulation of the rat jugular vein. J. Appl. Physiol. 36:1974;391-392
28. Hoyer D., Hannon J.P., Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71:2002;533-554
29. Javed A., Kamradt M.C., Van de Kar L.D., Gray T.S. D-Fenfluramine induces serotonin-mediated Fos expression in corticotropin-releasing factor and oxytocin neurons of the hypothalamus, and serotonin-independent Fos expression in enkephalin and neurotensin neurons of the amygdala. Neuroscience. 90(3):1999;851-858
30. Kirchgessner A.L., Gershon M.D. Innervation of the pancreas by neurons in the gut. J. Neurosci. 10:1990;1626-1642
31. Landsberg L. Diabetes, obesity and hypertension: role of insulin and sympathetic nervous system. Cardiovasc. Risk Factors. 3:1993;153-158
32. Lenz H.J., Raedler A., Greten H., Brown M.R. CRF initiates biological actions within the brain that are observed in response to stress. Am. J. Physiol. 252:1987;R34-R39
33. Lin M.T., Shian L.R. Stimulation of 5-hydroxytryptamine nerve cells in dorsal and median raphe nuclei elevates blood glucose in rats. Pflugers Arch. 417:1991;441-445
34. Maura G., Andrioli G.C., Cavazzani P., Raiteri M. 5-Hydroxytryptamine 3 receptors sided on cholinergic axon terminals of human cerebral cortex mediate inhibition of acetylcholine release. J. Neurochem. 58:1992;2334-2337
35. Mongeau R., Blier P., de Montigny C. The serotonergic and noradrenergic systems of the hippocampus. Their interactions and effects of antidepressant treatments. Brain Res. Rev. 23:1997;145-195
36. Nakajima S., Kitamura N., Yamada J., Yamashita T., Watanabe T. Immunohistochemical study on the endocrine pancreas of cattle with special reference to coexistence of serotonin and glucagon or bovine pancreatic polypeptide. Acta Anat. (Basel). 131:1988;235-240
37. Nandi J., Meguid M.M., Inui A., Xu Y., Makarenko I.G., Tada T., Chen C. Central mechanisms involved with catabolism. Curr. Opin. Clin. Nutr. Metab. Care. 5:2002;407-418
38. Nonogaki K., Iguchi A. Role of central neural mechanisms in the regulation of hepatic glucose metabolism. Life Sci. 60:1997;797-807
39. Oswald P., Souery D., Mendlewicz J. Fluvoxamine-induced hyperglycaemia in a diabetic patient with comorbid depression. Int. J. Neuropsychopharmacol. 6:2003;85-87
40. 1A receptor subtype in the paraventricular nuclei of the hypothalamus induces CRH and ACTH release in the rat. Neuroendocrinology. 56:1992;797-802
41. Pollack P.T., Mukherjee S.D., Fraser A.D. Sertraline-induced hypoglycemia. Ann. Pharmacother. 35:2001;1371-1374
42. Pontiroli A.E., Micossi P., Foá P.P. Effects of serotonin, of its biosynthetic precursors and of the anti-serotonin agent metergoline on the release of glucagon and insulin from rat pancreas. Horm. Metab. Res. 10:1978;200-203
43. Price M.L., Curtis A.L., Kirby L.G., Valentino R.J., Lucki I. Effects of corticotropin-releasing factor on brain serotonergic activity. Neuropsychopharmacology. 18(6):1998;492-502
44. Raap D.K., Van de Kar L.D. Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci. 65:1999;1217-1235
45. Rivier J., Rivier C., Vale W. Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science. 224:1984;889-891
46. Steffens A.B., Strubbe J.H., Balkan B., Scheurink A.J.W. Neuroendocrine factors regulating blood glucose, plasma FFA and insulin in the development of obesity. Brain Res. Bull. 27:1991;505-510
47. Sugimoto Y., Inoue K., Yamada J. Involvement of serotonin in zimelidine-induced hyperglycemia in mice. Biol. Pharm. Bull. 22:1999;1240-1241
48. Sugimoto Y., Yamada J., Yoshikawa T., Horisaka K. Effects of the 5-HT2C/2B receptor agonist 1-(3-chlorophenyl)piperazine on the plasma glucose levels of rats. Eur. J. Pharmacol. 307:1996;75-80
49. Wieczorek I., Schulz C., Jarry H., Lehnert H. The effects of the selective serotonin reuptake-inhibitor fluvoxamine on body weight in Zucker rats are mediated by corticotropin-releasing hormone. Int. J. Obes. Relat. Metab. Disord. 25:2001;1566-1569
50. Wong K.L., Tyce G.M. Effect of the administration of L-5- hydroxytryptophan and a monoamine oxidase inhibitor on glucose metabolism in rat brain. J. Neurochem. 31:1978;613-620
51. Yamada J., Sugimoto Y., Inoue K. Selective serotonin reuptake inhibitors fluoxetine and fluvoxamine induce hyperglycemia by different mechanisms. Eur. J. Pharmacol. 382:1999;211-215
52. 2B/2C receptors. Eur. J. Pharmacol. 359:1998;185-190